Friday, July 10, 2026

pharma · Amyotrophic Lateral Sclerosis · Acute Myeloid Leukemia

AB Science

AB Science is a pharma organization headquartered in PARIS, FR. Primary therapeutic focus areas include Amyotrophic Lateral Sclerosis, Acute Myeloid Leukemia, Mastocytosis, Mast cell activation syndrome, Multiple Scleros

PARIS, FR HQ
20 Employees
EMA registrant Type
Company details
Status
Public
HQ
PARIS, FR
Employees
20
Programs
6
Drugs
11
Patents
25
Clinical program

AB18001

Phase 2 · small molecule · Acute Myeloid Leukemia

AB18001 for Acute Myeloid Leukemia is a Phase 2 program (small_molecule) at AB Science with 1 ClinicalTrials.gov record(s).

← All AB Science projects Phase 2 small molecule active

Internal code AB18001

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
AB Science
Phase
Phase 2
Modality
small_molecule
Indication
Acute Myeloid Leukemia
Status
active
Trials
1